Zacks Investment Research downgraded shares of Trevena Inc. (NASDAQ:TRVN) from a hold rating to a sell rating in a research note issued to investors on Thursday.

According to Zacks, “Trevena, Inc. is a biopharmaceutical company. It focuses on discovering and developing therapeutics for G protein coupled receptors. The Company’s product pipeline includes TRV027, TRV130, TRV734 and Delta opioid biased ligand which are in different clinical phases. Trevena, Inc. is based in King of Prussia, Pennsylvania. “

Several other equities analysts also recently weighed in on TRVN. Jefferies Group reissued a buy rating on shares of Trevena in a research report on Friday, August 5th. Brean Capital set a $14.00 price target on Trevena and gave the stock a buy rating in a research report on Monday. FBR & Co reissued a buy rating and set a $13.00 price target on shares of Trevena in a research report on Thursday, August 4th. Cowen and Company reissued a buy rating and set a $13.00 price target on shares of Trevena in a research report on Friday, August 5th. Finally, TheStreet downgraded Trevena from a hold rating to a sell rating in a research report on Friday, June 17th. Two investment analysts have rated the stock with a sell rating and nine have given a buy rating to the stock. The stock presently has an average rating of Buy and an average target price of $14.30.

Analyst Recommendations for Trevena (NASDAQ:TRVN)

Trevena (NASDAQ:TRVN) traded down 0.31% during trading on Thursday, reaching $6.42. The company had a trading volume of 105,796 shares. Trevena has a 12 month low of $5.58 and a 12 month high of $13.02. The firm’s 50 day moving average is $6.93 and its 200-day moving average is $7.21. The company’s market capitalization is $334.98 million.

Trevena (NASDAQ:TRVN) last released its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.36) by $0.01. Trevena had a negative net margin of 841.00% and a negative return on equity of 45.01%. On average, equities analysts expect that Trevena will post ($1.55) earnings per share for the current year.

Large investors have recently modified their holdings of the company. State Street Corp increased its stake in shares of Trevena by 7.9% in the first quarter. State Street Corp now owns 412,015 shares of the biopharmaceutical company’s stock valued at $3,407,000 after buying an additional 30,257 shares during the last quarter. Wellington Management Group LLP increased its stake in shares of Trevena by 47.0% in the first quarter. Wellington Management Group LLP now owns 5,714,773 shares of the biopharmaceutical company’s stock valued at $47,262,000 after buying an additional 1,827,970 shares during the last quarter. National Planning Corp increased its stake in shares of Trevena by 21.9% in the first quarter. National Planning Corp now owns 19,452 shares of the biopharmaceutical company’s stock valued at $151,000 after buying an additional 3,500 shares during the last quarter. Vivo Capital LLC bought a new stake in shares of Trevena during the first quarter valued at $9,924,000. Finally, First Manhattan Co. bought a new stake in shares of Trevena during the second quarter valued at $729,000. 75.43% of the stock is owned by institutional investors.

About Trevena

Trevena Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and intends to commercialize therapeutics that use an approach to target G protein coupled receptors (GPCRs). Using its product platform, the Company has identified and advanced three differentiated product candidates: Oliceridine (TRV130), TRV027 and TRV250.

5 Day Chart for NASDAQ:TRVN

Receive News & Stock Ratings for Trevena Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena Inc. and related stocks with our FREE daily email newsletter.